EU delays approval of Novavax's revised COVID vaccine

European Union (EU) regulators have delayed a decision to give approval for Novavax's (NVAX.O) variant-tailored COVID-19 vaccine, the company said on Sunday.

The European Medicines Agency (EMA) has requested more information from Novavax on the shot, which targets the XBB variant, the company said.